Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols

Go online to PeerView.com/KPJ860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Recent clinical developments have transformed the
management of graft-versus-host disease (GVHD) and have the
potential to increase access to transplants and improve post-HCT
outcomes. These advances are centered on the emergence and
continued research of several novel modalities, including the BTK
inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell
co-stimulation blocking agent abatacept, as well as additional
novel strategies being tested in a range of acute and chronic GVHD
settings. In this activity from the 2022 Tandem meetings, our
expert panelists distill the current evidence on novel therapeutics
in the prevention and treatment of GVHD; throughout, they
illustrate how and when to integrate novel therapeutics into care,
provide guidance on how to prepare for emerging strategies, and
offer practical takeaways on the changing nature of GVHD
management. Upon completion of this activity, participants should
be better able to: Discuss current evidence supporting the use of
novel therapeutics as prophylactic or treatment options for acute
or chronic graft-versus-host disease (GVHD) in the post-transplant
setting, including JAK and BTK inhibitors, T-cell blocking agents,
α1-antitrypsin, and ROCK inhibitors, among others, Develop
management plans informed by evidence and practice guidelines that
incorporate novel therapeutics into the management of acute GVHD,
Integrate novel and emerging therapies into management plans for
the management of chronic GVHD, including novel combinatorial
strategies and/or options for second-line management.